Kodiak Sciences Inc (KOD): Price and Financial Metrics
GET POWR RATINGS... FREE!
KOD Stock Price Chart Interactive Chart >
KOD Price/Volume Stats
|Current price||$7.60||52-week high||$26.39|
|Prev. close||$7.74||52-week low||$4.90|
|Day high||$7.91||Avg. volume||1,521,988|
|50-day MA||$9.85||Dividend yield||N/A|
|200-day MA||$9.62||Market Cap||395.50M|
Kodiak Sciences Inc (KOD) Company Bio
Kodiak Sciences is a clinical stage biopharma specializing in therapeutics to treat chronic retinal diseases. The company was founded in 2005 and is based in New York City, New York.
Most Popular Stories View All
KOD Latest News Stream
|Loading, please wait...|
KOD Latest Social Stream
View Full KOD Social Stream
Latest KOD News From Around the Web
Below are the latest news stories about KODIAK SCIENCES INC that investors may wish to consider to help them evaluate KOD as an investment opportunity.
If you want to know who really controls Kodiak Sciences Inc. ( NASDAQ:KOD ), then you'll have to look at the makeup of...
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 2022 Morgan Stanley Healthcare Conference in New York, NY on Wednesday, September 14, 2022, at 1:05 p.m. Pacific Time (4:05 p.m. Eastern Time).
Kodiak Sciences (KOD) has progressed well with the development of its lead pipeline candidate, tarcocimab, for treating various retinal vascular diseases.
Kodiak Sciences (KOD) lead pipeline candidate, tarcocimab, being developed for treating various retinal vascular diseases, holds potential. Stiff competition in the market remains a woe.
KOD Price Returns